ClinicalTrials.gg
RecruitingNCT06227910VICTRIVAUpdated May 27, 2026

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

A Phase 3 interventional study of Vedolizumab and Upadacitinib in Crohn's Disease, sponsored by Takeda. Recruiting at 138 sites in 26 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Planned enrollment
7th of 39
396 · median 101
Started
2025
with 3 others
Phase 3
16 of 39
6 open now
Primary completion
2027-06
later than 2 of 11 live
Registered
36th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 36th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants.

All participants will receive DTT (either vedolizumab and upadacitinib or vedolizumab and placebo) for 12 weeks. Participants responding to the treatment will then receive vedolizumab only (monotherapy) for an additional 40 weeks.

During the study, participants will visit their study clinic 15 times.

Read the detailed description

The drug being tested in this study is vedolizumab. Vedolizumab is being tested to treat people with moderately to severely active CD. The study will look at the efficacy and safety of vedolizumab with and without upadacitinib. The study will enroll approximately 396 patients. Participants will be assigned in a 1:1 ratio to one of the two treatment groups in the 12-weeks Induction Phase:

  • Induction Phase: Vedolizumab + Upadacitinib
  • Induction Phase: Vedolizumab + Placebo

Participants who achieve a Crohn's disease activity index (CDAI) reduction of greater than or equal to (>=)70 points from baseline at Week 12 will enter the main study Maintenance Phase (40 weeks) of the study to receive vedolizumab monotherapy. Participants will be followed for a further 18-week safety follow-up period up to Week 70.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 70 weeks.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has a diagnosis of CD established at least 3 months before screening by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. The participant has a confirmed diagnosis of moderately to severely active CD as assessed by CDAI of 220-450.
  3. The participant has evidence of mucosal inflammation based on the SES-CD: SES-CD score of >=6 (or >=4 for participants with isolated ileal disease), as confirmed by a central reader.
  4. The participant has demonstrated an inadequate response to, loss of response to, or intolerance to , immunomodulators, or biologic therapy.

Exclusion criteria

Exclusion Criteria:

  1. The participant has a current diagnosis of ulcerative colitis or indeterminate colitis.
  2. The participant has infection(s) requiring treatment with IV anti-infectives within 30 days prior to baseline or oral/intramuscular anti-infectives within 14 days prior to baseline.
  3. The participant has evidence of an active infection during the screening period, or infection within 30 days prior to screening, or ongoing chronic infection.
  4. The participant has a history of recurrent or disseminated (including a single episode) herpes zoster, or disseminated (including a single episode) herpes simplex.
  5. The participant has any of the following ongoing known complications of CD: abscess (abdominal or peri-anal); symptomatic bowel strictures; 2 entire missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum; fulminant colitis; toxic megacolon; or any other manifestation that might require surgery while enrolled in the study.
  6. The participant has an ostomy or ileoanal pouch.
  7. The participant has severe renal impairment, defined as an estimated of \<30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2).
  8. The participant has severe ( C) hepatic impairment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    Double-blind Induction Phase: Vedolizumab + Upadacitinib

    Participants will receive vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, 6 and 10 along with upadacitinib 45 mg, orally, once daily (QD) for 12 weeks.

    Drug: Vedolizumab · Drug: Upadacitinib

  • Placebo comparator
    Double-blind Induction Phase: Vedolizumab + Placebo

    Participants will receive vedolizumab IV 300 mg infusion, at Weeks 0, 2, 6 and 10 along with upadacitinib matched placebo, orally, QD for 12 weeks.

    Drug: Vedolizumab · Drug: Placebo

  • Experimental
    Main Study Maintenance Phase: Vedolizumab Monotherapy

    Participants who achieve a CDAI reduction of \>=70 points from baseline at Week 12 will receive vedolizumab 300 mg IV infusion (monotherapy), every 8 weeks (Q8W) starting at Week 14 to 52. The Q8W vedolizumab monotherapy may be escalated to Q4W at the investigator's discretion.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV infusion.

    Also known as: Entyvio, MLN0002, KYNTELES

  • Upadacitinib over-encapsulated tablets.

    Also known as: Rinvoq

  • DrugPlacebo

    Upadacitinib matched placebo capsules.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission Based on the CDAI at Week 12

    Clinical remission is defined as a CDAI score of less than (\<) 150 points. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit, and body weight. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: Week 12

  2. Percentage of Participants Exhibiting an Endoscopic Response Based on Simple Endoscopic Score for CD (SES-CD) at Week 12

    Endoscopic response per SES-CD is defined as decrease in SES CD greater than (\>) 50% from baseline (or for participants with isolated ileal disease, SES-CD \<=4 or a \>=2-point reduction in SES-CD from baseline) read centrally. SES-CD evaluates 4 endoscopic variables (ulcer size,percentage of ulcerated and affected surface area, presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy (ileum,right,transverse,and left colon,rectum). Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of the scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. Overall SES-CD score ranges from 0 to 56 and is sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving 2-item Patient-reported Outcome Measure (PRO2) Based Clinical Remission at Week 12

    Clinical remission based on PRO2 is defined as 7-day average of very soft or liquid stool frequency (SF) less than or equal to ( \<=) 2.8, 7-day average of abdominal pain (AP) score \<=1.0, and neither worse than baseline. The PRO2 is comprised of the stool frequency and abdominal pain components of the CDAI.

    Time frame: Week 12

  2. Percentage of Participants Achieving Endoscopic Remission Based on SES-CD at Week 12

    Endoscopic remission as per SES-CD is defined as a SES-CD score of \<=4 and no subscore \>1, read centrally. SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of surface area (SA) that is ulcerated, percentage of SA affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease.

    Time frame: Week 12

  3. Percentage of Participants Exhibiting Corticosteroid-free Clinical Remission in Participants who Were Taking Corticosteroids at Baseline Based on the CDAI at Week 12

    Percentage of participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission per CDAI at Week 12 will be reported. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit, and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: Week 12

  4. Percentage of Participants Exhibiting a Clinical Response Based on the CDAI at Week 12

    Clinical response is defined as \>=100-point decrease from baseline in CDAI score. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit, and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: Week 12

  5. Percentage of Participants Achieving Clinical Remission Based on the CDAI at Week 52

    Clinical remission is defined as a CDAI score of \<150 points. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit, and body weight. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: Week 52

  6. Percentage of Participants Exhibiting an Endoscopic Response Based on SES-CD at Week 52

    Endoscopic response per SES-CD is defined as a decrease in SES CD \>50% from baseline (or for participants with isolated ileal disease,SES-CD \<=4 or a \>=2-point reduction in SES-CD from baseline) read centrally. SES-CD evaluates 4 endoscopic variables (ulcer size,percentage of ulcerated and affected surface area,presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy (ileum,right,transverse,and left colon,and rectum). Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. Overall SES-CD score ranges from 0 to 56 and is sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease.

    Time frame: Week 52

  7. Percentage of Participants Achieving 2-item PRO2 Based Clinical Remission at Week 52

    Clinical remission based on PRO2 is defined as 7-day average of very soft or liquid stool frequency (SF) \<=2.8, 7-day average of abdominal pain (AP) score \<=1.0, and neither worse than baseline. The PRO2 is comprised of the stool frequency and abdominal pain components of the CDAI.

    Time frame: Week 52

  8. Percentage of Participants Achieving Endoscopic Remission Based on SES-CD at Week 52

    Endoscopic remission as per SES-CD is defined as a SES-CD score of \<=4 and no subscore \>1, read centrally . SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of surface area (SA) that is ulcerated, percentage of SA affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease.

    Time frame: Week 52

  9. Percentage of Participants Exhibiting Corticosteroid-free Clinical Remission in Participants who Were Taking Corticosteroids at Baseline Based on the CDAI at Week 52

    Percentage of participants using oral corticosteroids at baseline who have discontinued corticosteroids and are in clinical remission at Week 52 per CDAI will be reported. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit, and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity

    Time frame: Week 52

  10. Percentage of Participants Exhibiting a Clinical Response Based on the CDAI at Week 52

    Clinical response is defined as \>=100-point decrease from baseline in CDAI score. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit, and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity.

    Time frame: Week 52

07

Study locations

8 of 138 sites recruiting
  • UCSD Medical Center
    La Jolla, California 92037, United States
    Not yet recruiting
  • Keck Medicine Of USC - USC Healthcare Center 1
    Los Angeles, California 90033, United States
    Not yet recruiting
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
    Recruiting
    • Site Contact · Contactbpatel@peakgastro.com · 719-310-6719
    • Bhaktasharan Patel · Principal investigator
  • GI PROS, Inc.
    Naples, Florida 34102, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Orlando Health Ambulatory Care Center
    Orlando, Florida 32806, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • USF Health Morsani Center for Advanced Healthcare
    Tampa, Florida 33612, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Indiana University (IU) Health University Hospital
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Kentucky
    Lexington, Kentucky 40536, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Mount Sinai Hospital - The Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical Center
    New York, New York 10029-5204, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Columbia University Medical Center, New York-Presbyterian Hospital
    New York, New York 10032, United States
    Not yet recruiting
  • Lenox Hill Hospital Northwell Health
    New York, New York 10075, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gastroenterology Associates
    Greenville, South Carolina 29607, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Rapid City Medical Center
    Rapid City, South Dakota 57701, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
    Recruiting
    • Site Contact · Contactjs_bull@yahoo.com · 210-581-2812
    • Jeff Bullock · Principal investigator
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
    Recruiting
    • Site Contact · Contactaarond@tylerri.com · 903-630-6211
    • George Duvall · Principal investigator
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
    Not yet recruiting
  • University of Washington Medical Center - Montlake
    Seattle, Washington 98195, United States
    Not yet recruiting
  • Medical College of Wisconsin Cancer Center - Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
    • Site Contact · Contactpbeniwal@mcw.edu · 414-955-6827
    • Poonam Beniwal-Patel · Principal investigator
  • Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) - Universitaetsklinik fuer Innere Medizin III
    Vienna, State of Vienna 1090, Austria
    Not yet recruiting
  • Medical University Innsbruck
    Innsbruck, Tyrol 6020, Austria
    Not yet recruiting
  • Johannes Kepler Universitat Linz (JKU)
    Linz, 4021, Austria
    Not yet recruiting
  • Landeskrankenhaus Salzburg, Innere Medizin I, Labor im Erdgeschoss
    Salzburg, 5020, Austria
    Not yet recruiting
    • Site Contact · Contacts.heeren@salk.at · 5725525410
    • Sonja Heeren · Principal investigator
  • Krankenhaus der Barmherzigen Brueder Wien
    Vienna, 1020, Austria
    Not yet recruiting
    • Site Contact · Contactaesere58@live.com · 1404004735
    • Alexander Eser · Principal investigator
  • Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Brussel
    Brussels, Anderlecht 1070, Belgium
    Not yet recruiting
  • Imelda GI Clinical Research Center
    Bonheiden, 2820, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Not yet recruiting
  • University Hospitals Leuven
    Leuven, 3000, Belgium
    Not yet recruiting
  • Centre Hospitalier Chretien MontLegia
    Liège, 4000, Belgium
    Not yet recruiting
  • Hospital Universitario Cajuru
    Curitiba, Paraná 80050-350, Brazil
    Not yet recruiting
    • Site Contact · Contactpgkotze@hotmail.com · +55 4132537838
    • Paulo Kotze · Principal investigator
  • Faculdade de Medicina de Botucatu
    Botucatu, São Paulo 18618-970, Brazil
    Not yet recruiting
  • Centro de Estudos Clinico do Interior Paulista - CECIP
    Jaú, São Paulo 17201130, Brazil
    Not yet recruiting
    • Site Contact · Contactbrunameyercecip@gmail.com · +55 14 3622-0500; 98116-9078
    • Bruna Meyer de Mattos · Principal investigator
  • Pesquisare Saude
    Santo André, São Paulo 9080110, Brazil
    Not yet recruiting
    • Site Contact · Contactalexander@rolim.med.br · 11981118990
    • Alexander de Sa Rolim · Principal investigator
  • Universidade Federal do Rio de Janeiro (UFRJ)-Hospital Universitario Clementino Fraga Filho (HUCFF)
    Rio de Janeiro, 21941-617, Brazil
    Not yet recruiting
    • Site Contact · Contactc.zaltman@gmail.com · +552139382417
    • Cyrla Zaltman · Principal investigator
  • Hospital das Clinicas of the University of Sao Paulo (Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC/FMUSP))
    São Paulo, 05403-010, Brazil
    Not yet recruiting
  • Unidade de Pesquisa Clinica UPC Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
    São Paulo, 1405-1243, Brazil
    Not yet recruiting
  • Heritage Medical Research Clinic - University Of Calgary
    Calgary, Alberta T2N 4Z6, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Manitoba-Winnipeg Regional Health Authority-Health Sciences Centre
    Winnipeg, Manitoba R3A 1R9, Canada
    Not yet recruiting
  • Dalhousie University
    Halifax, Nova Scotia B3H 2Y9, Canada
    Not yet recruiting
  • Barrie GI Associates
    Barrie, Ontario L4M 7G1, Canada
    Recruiting
  • McMaster University - Farncombe Family Digestive Health Research Institute (FFDHRI)
    Hamilton, Ontario L8S 4K1, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Taunton Surgical Centre-Oshawa Clinic
    Oshawa, Ontario L1J 0C7, Canada
    Recruiting
    • Site Contact · Contactdaniel@drgreengi.com · 905-721-4964
    • Daniel Green · Principal investigator
  • Toronto Immune and Digestive Health Institute (TIDHI)
    Toronto, Ontario M6A 3B4, Canada
    Recruiting
    • Site Contact · Contactpi_research@tidhi.ca · 6478122113
    • Mark Silverberg · Principal investigator
  • Toronto Digestive Disease Associates
    Vaughan, Ontario L4L 4Y7, Canada
    Not yet recruiting
    • Site Contact · Contactdford@tdda.ca · 4166500017
    • David Ford · Principal investigator
  • Centre Hospitalier de l'Universite de Montreal
    Montreal, Quebec H2X 0A9, Canada
    Not yet recruiting
  • Poliklinika Borzan d.o.o.
    Osijek, 31000, Croatia
    Not yet recruiting
    • Site Contact · Contactvborzan@hotmail.com · 385915211171
    • Vladimir Borzan · Principal investigator
  • Clinical Hospital Center Rijeka
    Rijeka, 51000, Croatia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital Centre Sestre Milosrdnice
    Zagreb, 10000, Croatia
    Not yet recruiting
  • Nemocnice Ceske Budejovice, a.s.
    České Budějovice, 370 01, Czechia
    Not yet recruiting
  • Fakultni Nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
    Not yet recruiting
    • Site Contact · Contacttomas.douda@fnhk.cz · 21127048
    • Tomas Douda · Principal investigator
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Králové, 500 12, Czechia
    Not yet recruiting
  • IBD Clinical and Research centre
    Prague, 190 00, Czechia
    Not yet recruiting
  • Aalborg Hospital
    Aalborg, 9000, Denmark
    Not yet recruiting
    • Site Contact · Contactjaf@rn.dk · 97663501
    • Jan Fallingborg · Principal investigator
  • Hvidovre Hospital Medicinsk Gastroenterologisk Afdeling
    Hvidovre, 2650, Denmark
    Not yet recruiting
  • CHU d'Amiens-Picardie - Hopital SUD
    Amiens, 80054, France
    Not yet recruiting
  • Hopital Huriez - CHRU de Lille
    Lille, 59037, France
    Not yet recruiting
  • Chu - Hopital Nord
    Marseille, 13015, France
    Not yet recruiting
  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu
    Nantes, 44093, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Universitaire de Bordeaux - Hopital Haut-Leveque
    Pessac, 33600, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU St Etienne Hopital Nord
    Saint-Etienne, 42270, France
    Not yet recruiting
  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Rangueil
    Toulouse, 31059, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Regional Universitaire de Nancy, Hopital Brabois
    Vandœuvre-lès-Nancy, 54511, France
    Not yet recruiting
  • Krankenhaus Waldfriede e.V.
    Berlin, 14163, Germany
    Not yet recruiting
  • Agaplesion Markus Krankenhaus
    Frankfurt am Main, 60431, Germany
    Not yet recruiting
  • Studiengesellschaft BSF
    Halle, 06108, Germany
    Not yet recruiting
  • Universitaetsklinikum Jena
    Jena, 07747, Germany
    Not yet recruiting
  • Universitaetsklinikum Schleswig-Holstein, UKSH-Campus Kiel
    Kiel, 24105, Germany
    Not yet recruiting
    • Site Contact · Contacts.schreiber@mucosa.de · 4943150022457
    • Stefan Schreiber · Principal investigator
  • St. Marien- und St. Annastiftskrankenhaus
    Ludwigshafen, 67065, Germany
    Not yet recruiting
  • Universitaetsklinikum Mannheim (Umm) - Ii Medizinische Klinik
    Mannheim, 68167, Germany
    Not yet recruiting
  • University of Athens School of Medicine, Alexandra General Hospital
    Athens, Attica 11528, Greece
    Not yet recruiting
    • Site Contact · Contactevazamb@gmail.com · 6977252383
    • Evanthia Zampeli · Principal investigator
  • Metaxa Cancer Hospital
    Piraeus, Attica 185 37, Greece
    Not yet recruiting
    • Site Contact · Contactetsironi@yahoo.com · 6977009915
    • Eftychia Tsironi · Principal investigator
  • University Hospital of Heraklion
    Heraklion, Crete 71110, Greece
    Not yet recruiting
    • Site Contact · Contactikoutroub2@gmail.com · 302810392254
    • Ioannis Koutroubakis · Principal investigator
  • Central Hospital of Northern Pest - Military Hospital
    Budapest, 1062, Hungary
    Not yet recruiting
  • Semmelweis Egyetem
    Budapest, 1082, Hungary
    Not yet recruiting
  • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Szent-Gyorgyi Albert Klinikai Kozpont, I.Sz. Belogyaszati Klinika
    Szeged, 6720, Hungary
    Not yet recruiting
  • Adelaide, Meath and National Children's Hospital
    Dublin, 24, Ireland
    Not yet recruiting
  • University College Dublin (UCD) - St. Vincent's University Hospital (SVUH)
    Dublin, D04 T6F4, Ireland
    Not yet recruiting
    • Site Contact · Contactgdoherty@svhg.ie · 35312215212
    • Glen Doherty · Principal investigator
  • Beaumont Hospital
    Dublin, D09 V2N0, Ireland
    Not yet recruiting
  • Soroka Medical Center
    Beersheba, 8410101, Israel
    Not yet recruiting
    • Site Contact · Contactdorons@tlvmc.gov.il · 36973270
    • Doron Schwartz · Principal investigator
  • Rambam Health Care Campus (RHCC)
    Haifa, 3109601, Israel
    Not yet recruiting
  • Meir Medical Center
    Kfar Saba, 44281, Israel
    Not yet recruiting
  • Rabin Medical Center - Beilinson Campus (Beilinson and Hasharon Hospital)
    Petah Tikva, 49100, Israel
    Not yet recruiting
    • Site Contact · Contactiritab@clalit.org.il · 545989299
    • Irit Avni-Biron · Principal investigator
  • The Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
    Not yet recruiting
  • Ospedale San Raffaele (HSR) Instituto Scientifico Universitario San Raffaele
    Milan, 20132, Italy
    Not yet recruiting
    • Site Contact · Contactibd.trials@hsr.it · 282245555
    • Silvio Danese · Principal investigator
  • Azienda Ospedaliero Universitaria Federico II di Napoli
    Naples, 80131, Italy
    Not yet recruiting
    • Site Contact · Contactfabcasti@unina.it · 817463849
    • Fabiana Castiglione · Principal investigator
  • A. Gemelli University Hospital, Catholic University of the Sacred Heart
    Roma, 00168, Italy
    Not yet recruiting
  • Humanitas Clinical And Research Institute
    Rozzano, 20089, Italy
    Not yet recruiting
  • Fondazione IRCSS Casa Sollievo Della Sofferenza
    San Giovanni Rotondo, 71013, Italy
    Not yet recruiting
  • AO Ordine Mauriziano di Torino
    Torino, 10122, Italy
    Not yet recruiting
    • Site Contact · Contactmdaperno@gmail.com · 115082534
    • Marco Daperno · Principal investigator
  • Amsterdam UMC Research BV
    Amsterdam, 1105 AZ, Netherlands
    Not yet recruiting
  • Radboud University Medical Center
    Nijmegen, 6525 GA, Netherlands
    Not yet recruiting
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
    Not yet recruiting
  • Elisabeth TweeSteden Ziekenhuis (ETZ)
    Tilburg, 5022 GC, Netherlands
    Not yet recruiting
    • Site Contact · Contactm.lutgens@etz.nl · 013-2218466
    • Maurice Lutgens · Principal investigator
  • Vestre Viken HF - Baerum Sykehus
    Drammen, Gjettum 1309, Norway
    Not yet recruiting
    • Site Contact · Contactsthvat@vestreviken.no · 4791364749
    • Stine Astrup Hvattum · Principal investigator
  • Haukeland Universitetssjukehus (Haukeland University Hospital)
    Bergen, N5021, Norway
    Not yet recruiting
  • Akershus University Hospital
    Lorenskog, 1478, Norway
    Not yet recruiting
  • Oslo Universitetssykehus HF, Ulleval
    Oslo, 0424, Norway
    Not yet recruiting
    • Site Contact · Contactmoliho@ous-hf.no · 4722119260
    • Marte Lie Hoivik · Principal investigator
  • Oddzial Kliniczny Gastroenterologii Ogolnej i Onkologicznej SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Barlickiego Uniwersytetu Medycznego w Lodzi
    Lodz, 90-153, Poland
    Not yet recruiting
  • Samodzielny Publiczny Szpital Kliniczny Im. H. Swiecickiego Um
    Poznan, 60-354, Poland
    Not yet recruiting
    • Site Contact · Contactpiotr.eder@op.pl · 48691240477
    • Piotr Eder · Principal investigator
  • H-T. Centrum Medyczne Sp. z o.o. Sp.k.
    Tychy, 43-100, Poland
    Not yet recruiting

Showing the first 100 of 138 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Danese S, Sands BE, Feagan BG, Jairath V, Panaccione R, Peyrin-Biroulet L, Irving PM, Schreiber S, Dotan I, Ferrante M, D'Haens GR, Jones S, Freire M, Lindner D, Adsul S, Oberai P, Colombel JF. Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease. Contemp Clin Trials Commun. 2025 Nov 24;48:101574. doi: 10.1016/j.conctc.2025.101574. eCollection 2025 Dec. PubMed 41403476 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 29 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 29, 2024
StartActual
Jan 2, 2025
Primary completionEst.
Jun 8, 2027
CompletionEst.
Aug 1, 2028
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06227910
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Jan 2, 2025
Primary completion
Jun 8, 2027 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
May 27, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion